On August 5, AstraZeneca PLC rose 4.77% in pre-market trading, trading at approximately $163.08/share, with turnover of $27.4 million. The stock is recovering from a sharp decline of over 9% earlier this week following reports of merger talks with Bristol-Myers Squibb.

Multiple investment banks have cast doubt on the proposed $400 billion combination. BMO Capital noted that neither company has sufficient financial capacity to acquire the other, estimating AstraZeneca could raise approximately $37 billion — far below the funds required. RBC Capital Markets stated the deal is unlikely as AstraZeneca shareholders broadly oppose the transaction, questioning the rationale and expressing concerns about growth dilution. Separately, AstraZeneca signed a joint venture contract with CSPC Pharmaceutical Group, sending a positive signal on business expansion.

With market expectations for the mega-merger cooling significantly, the previously oversold stock is experiencing a technical recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)